Amarin Corporation (AMRN) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Amarin Corporation

NasdaqCM•Healthcare•Drug Manufacturers - General

$14.02-0.37(-0.03%)Market open

Market Cap

$5.78B

P/S

31.1x

P/B

13.0x

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (9/25).

Profitability14/25

Growth9/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality11/25

Strengths

Long cash runwayInterest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 3439.8x5y range 3439.8x – 3439.8x

P/S · 31.1x5y range 15.8x – 67.3x

Currently near its 20-quarter median.

P/B · 13.0x5y range 7.5x – 63.5x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $5.78B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $186.23M
Q. Revenue: $42.21M
TTM EBITDA: $-37.93M
TTM Op. Income: $-40.77M
Q. Op. Income: $-12.01M
TTM Net Income: $-27.12M
Q. Net Income: $-7.65M
EPS: $-0.02
Shares Out.: $416.44M

$186.23M in TTM revenue declined 15.1% YoY, reaching $42.21M last quarter. TTM EBITDA of $-37.93M and TTM operating income of $-40.77M show growth is flowing through to the bottom line. However, net income is negative at $27.12M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 15% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 35.5%
EBITDA Margin: -26.9%
Op. Margin: -28.5%
Net Margin: -18.1%

Op. margin of -28.5% is down 6.5% YoY — costs are rising relative to revenue. Net margin at -18.1% and gross margin of 35.5% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 31.1x
P/B Ratio: 13.0x

P/S of 31.1x and P/B of 13.0x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $624.36M
Cash: $143.56M
Long-Term Debt: N/A
Book Value: $443.62M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $6.60M
TTM Free Cash Flow: $15.57M
FCF Margin: 8.4%
FCF / Net Income: -0.6

TTM FCF of $15.57M on $6.60M in operating cash flow. The FCF / Net Income ratio of -0.6x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is up 235% — a weakening trend.